The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma.
- Published in:
- Veterinary & Comparative Oncology, 2020, v. 18, n. 1, p. 52, doi. 10.1111/vco.12526
- By:
- Publication type:
- Article
Works by Ormonde, Amanda R.
Results: 2
1
2
A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma.
- Published in:
- PLoS ONE, 2018, v. 13, n. 12, p. 1, doi. 10.1371/journal.pone.0209941
- By:
- Publication type:
- Article